Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

John Maraganore in "Biotechnology in the Time of COVID-19: Commentaries from the Front Line"

June 9, 2020

Alnylam Pharmaceuticals

Covid-19 has fundamentally changed the way that people all over the world live and work. In the midst of this pandemic, people and companies within the biopharmaceutical industry are rising to the challenge of developing new vaccines and treatments, united by a common purpose to respond to perhaps the greatest public health threat of our lifetimes. In a new e-book, dozens of biopharma industry leaders, including our CEO John Maraganore, share their perspectives from the industry's unique vantage point on the front line.

In his chapter titled "Science and Innovation are the Answers," John shares his thoughts on how the sense of urgency of this moment and the scientific advancements made over decades is enabling velocity and a level of collaboration across companies previously unseen in drug development.  He also discusses why RNA interference, which Alnylam has pioneered, could be uniquely suited to combat SARS-CoV-2 (the virus that causes the disease COVID-19) and other coronaviruses and discusses our own COVID-19 therapeutic program with partner Vir Biotechnology.

Download your copy of Biopharma in the Time of COVID-19: Commentaries from the Front Line, available for free through June 12 in the Amazon Kindle store here. After June 12, the editor royalties and a portion of publisher revenues will be donated to two nonprofits focused on rare disease research: Global Genes (globalgenes.org) and The Institute for Life Changing Medicines (lifechangingmedicines.org).

Alnylam John Maraganore COVID-19 Book Chapter

From the publisher:

Pandemics have killed at least a half billion people over the past two millennia. Today a new plague, COVID-19, is stalking humanity. But in the age of biotechnology, humanity is no longer defenseless. Biotechnology in the Time of COVID-19 is a collection of stories about the biotechnology industry—its purpose, its people and how it has risen to battle the COVID-19 virus—told by forty-seven leaders of that industry in their own words.

The industry is an ecosystem of scientists, doctors, patients, entrepreneurs, investors, bankers, analysts and reporters, all committed to treating and curing disease. It has been built over the past forty years, producing medical advances at an electrifying rate. As the COVID-19 pandemic emerged, within just two months hundreds of companies had pivoted to apply their technologies to combat the virus.

The contributors to this book offer inside views of this seminal industry, historical and personal perspectives, lessons learned, and looks into to the future. Diverse as these leaders are, they are united by their conviction that science and medicine will light humanity’s way to greater health and longevity than it has ever known.

 

Tags

Leadership, Articles, John Maraganore, COVID-19, Infectious Diseases, Executive Team

Related Content See All News ›
Leadership Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders
Leadership Leading by Example in Gender Diversity Among Executive Leadership
Leadership Alnylam Named One of Fast Company's Most Innovative Companies for 2023

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Leadership Alnylam BioVenture Challenge: Supporting the Next Generation of Biotech Leaders
Leadership Leading by Example in Gender Diversity Among Executive Leadership
Leadership Alnylam Named One of Fast Company's Most Innovative Companies for 2023
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site